Summary

The global Nucleic Acid Drugs market is projected to grow from US$ 14636 million in 2024 to US$ 21722 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.43% during the forecast period.
The North America market for Nucleic Acid Drugs is estimated to increase from $ 8327.53 million in 2024 to reach $ 11827 million by 2031, at a CAGR of 6.4% during the forecast period of 2025 through 2031.
The China market for Nucleic Acid Drugs is estimated to increase from $ 81.1 million in 2024 to reach $ 1231.84 million by 2031, at a CAGR of 44.83% during the forecast period of 2025 through 2031.
The Europe market for Nucleic Acid Drugs is estimated to increase from $ 3316.94 million in 2024 to reach $ 6063.24 million by 2031, at a CAGR of 10.64% during the forecast period of 2025 through 2031.
The global key companies of Nucleic Acid Drugs include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc. In 2024, the global top five players had a share approximately 86.47% in terms of revenue.

Report Includes
This report presents an overview of global market for Nucleic Acid Drugs market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Nucleic Acid Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Nucleic Acid Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nucleic Acid Drugs revenue, market share and industry ranking of main companies, data from 2020 to 2024. Identification of the major stakeholders in the global Nucleic Acid Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Nucleic Acid Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc.

Market Segmentation
By Company
On Market Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
Novo Nordisk
AstraZeneca
Astellas Pharma

On Pipeline Company
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics

Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA

Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other

By Region
North America
United States
Canada

China

Asia-Pacific
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia

Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe

Latin America
Mexico
Brazil
Rest of Latin America

Middle East & Africa
Middle East
Africa


Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Nucleic Acid Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Drugs companies‘ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

ページTOPに戻る

Table of Contents

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Nucleic Acid Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031 1
1.2.2 Antisense Oligonucleotides (ASO) 3
1.2.3 siRNA 5
1.2.4 mRNA 6
1.3 Market by Application 7
1.3.1 Global Nucleic Acid Drugs Market Share by Application: 2020 VS 2024 VS 2031 8
1.3.2 Neuromuscular Diseases 10
1.3.3 hATTR 10
1.3.4 COVID-19 11
1.4 Assumptions and Limitations 12
1.5 Study Objectives 13
1.6 Years Considered 14
2 Global Growth Trends 15
2.1 Global Nucleic Acid Drugs Market Perspective (2020-2031) 15
2.2 Global Nucleic Acid Drugs Growth Trends by Region 16
2.2.1 Global Nucleic Acid Drugs Market Size by Region: 2020 VS 2024 VS 2031 17
2.2.2 Nucleic Acid Drugs Market Size by Region (2020-2031) 18
2.3 Nucleic Acid Drugs Market Dynamics 20
2.3.1 Nucleic Acid Drugs Industry Trends 20
2.3.2 Nucleic Acid Drugs Market Drivers 21
2.3.3 Nucleic Acid Drugs Market Challenges 22
2.3.4 Nucleic Acid Drugs Market Restraints 22
3 Competition Landscape by Key Players 24
3.1 Global Revenue Nucleic Acid Drugs by Players 24
3.1.1 Global Nucleic Acid Drugs Revenue by Players (2020-2025) 24
3.1.2 Global Nucleic Acid Drugs Revenue Market Share by Players (2020-2025) 25
3.2 Global Nucleic Acid Drugs Market by Company Type (Tier 1, Tier 2, and Tier 3) 26
3.3 Global Key Players of Nucleic Acid Drugs, Ranking by Revenue, 2023 VS 2024 VS 2025 27
3.4 Global Market Concentration Ratio 28
3.4.1 Global Nucleic Acid Drugs Market Concentration Ratio (CR5 and HHI) 28
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Drugs Revenue in 2024 29
3.5 Global Key Players of Nucleic Acid Drugs Head office and Area Served 30
3.6 Global Key Players of Nucleic Acid Drugs, Product and Application 31
3.7 Global Key Players of Nucleic Acid Drugs, Date of Enter into This Industry 33
3.8 Mergers & Acquisitions, Expansion Plans 33
4 Breakdown Data by Type 37
4.1 Global Nucleic Acid Drugs Historic Market Size by Type (2020-2025) 37
4.2 Global Nucleic Acid Drugs Forecasted Market Size by Type (2026-2031) 38
5 Breakdown Data by Application 39
5.1 Global Nucleic Acid Drugs Historic Market Size by Application (2020-2025) 39
5.2 Global Nucleic Acid Drugs Forecasted Market Size by Application (2026-2031) 40
6 North America 41
6.1 North America Nucleic Acid Drugs Market Size (2020-2031) 41
6.2 North America Market Size by Type 41
6.2.1 North America Nucleic Acid Drugs Market Size by Type (2020-2031) 41
6.2.2 North America Nucleic Acid Drugs Market Share by Type (2020-2031) 42
6.3 North America Market Size by Application 43
6.3.1 North America Nucleic Acid Drugs Market Size by Application (2020-2031) 43
6.3.2 North America Nucleic Acid Drugs Market Share by Application (2020-2031) 44
6.4 North America Market Size by Country 44
6.4.1 North America Nucleic Acid Drugs Market Size by Country: 2020 VS 2024 VS 2031 44
6.4.2 North America Nucleic Acid Drugs Market Size by Country (2020-2031) 45
6.4.3 United States 46
6.4.4 Canada 46
7 Europe 47
7.1 Europe Nucleic Acid Drugs Market Size (2020-2031) 47
7.2 Europe Market Size by Type 47
7.2.1 Europe Nucleic Acid Drugs Market Size by Type (2020-2031) 47
7.2.2 Europe Nucleic Acid Drugs Market Share by Type (2020-2031) 48
7.3 Europe Market Size by Application 48
7.3.1 Europe Nucleic Acid Drugs Market Size by Application (2020-2031) 48
7.3.2 Europe Nucleic Acid Drugs Market Share by Application (2020-2031) 49
7.4 Europe Market Size by Country 50
7.4.1 Europe Nucleic Acid Drugs Market Size by Country: 2020 VS 2024 VS 2031 50
7.4.2 Europe Nucleic Acid Drugs Market Size by Country (2020-2025) 50
7.4.3 Germany 52
7.4.4 France 52
7.4.5 U.K. 53
7.4.6 Italy 53
7.4.7 Russia 54
8 China 55
8.1 China Nucleic Acid Drugs Market Size (2020-2031) 55
8.2 China Market Size by Type 55
8.2.1 China Nucleic Acid Drugs Market Size by Type (2020-2031) 55
8.2.2 China Nucleic Acid Drugs Market Share by Type (2020-2031) 56
8.3 China Market Size by Application 57
8.3.1 China Nucleic Acid Drugs Market Size by Application (2020-2031) 57
8.3.2 China Nucleic Acid Drugs Market Share by Application (2020-2031) 58
9 Asia (excluding China) 59
9.1 Asia Nucleic Acid Drugs Market Size (2020-2031) 59
9.2 Asia Market Size by Type 59
9.2.1 Asia Nucleic Acid Drugs Market Size by Type (2020-2031) 59
9.2.2 Asia Nucleic Acid Drugs Market Share by Type (2020-2031) 60
9.3 Asia Market Size by Application 61
9.3.1 Asia Nucleic Acid Drugs Market Size by Application (2020-2031) 61
9.3.2 Asia Nucleic Acid Drugs Market Share by Application (2020-2031) 62
9.4 Asia Market Size by Region 62
9.4.1 Asia Nucleic Acid Drugs Market Size by Region: 2020 VS 2024 VS 2031 62
9.4.2 Asia Nucleic Acid Drugs Market Size by Region (2020-2031) 63
9.4.3 Japan 64
9.4.4 South Korea 65
9.4.5 Southeast Asia 65
9.4.6 India 66
9.4.7 Australia 66
10 Middle East, Africa, and Latin America 67
10.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size (2020-2031) 67
10.2 Middle East, Africa, and Latin America Market Size by Type 67
10.2.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type (2020-2031) 67
10.2.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Type (2020-2031) 68
10.3 Middle East, Africa, and Latin America Market Size by Application 69
10.3.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application (2020-2031) 69
10.3.2 Middle East, Africa, and Latin America Market Share by Application (2020-2031) 70
10.4 Middle East, Africa, and Latin America Market Size by Country 70
10.4.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country: 2020 VS 2024 VS 2031 70
10.4.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country (2020-2031) 71
10.4.3 Brazil 72
10.4.4 Mexico 72
10.4.5 Middle East 73
10.4.6 Africa 73
11 Key Players Profiles 74
11.1 Sarepta Therapeutics 74
11.1.1 Sarepta Therapeutics Company Details 74
11.1.2 Sarepta Therapeutics Business Overview 74
11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Introduction 75
11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025) 76
11.1.5 Sarepta Therapeutics Recent Development 76
11.2 Ionis Pharmaceuticals 77
11.2.1 Ionis Pharmaceuticals Company Details 77
11.2.2 Ionis Pharmaceuticals Business Overview 77
11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Introduction 78
11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2020-2025) 80
11.2.5 Ionis Pharmaceuticals Recent Development 80
11.3 Alnylam 81
11.3.1 Alnylam Company Details 81
11.3.2 Alnylam Business Overview 81
11.3.3 Alnylam Nucleic Acid Drugs Introduction 82
11.3.4 Alnylam Revenue in Nucleic Acid Drugs Business (2020-2025) 83
11.3.5 Alnylam Recent Development 84
11.4 Biogen 84
11.4.1 Biogen Company Details 84
11.4.2 Biogen Business Overview 85
11.4.3 Biogen Nucleic Acid Drugs Introduction 85
11.4.4 Biogen Revenue in Nucleic Acid Drugs Business (2020-2025) 87
11.4.5 Biogen Recent Development 87
11.5 Nippon Shinyaku 88
11.5.1 Nippon Shinyaku Company Details 88
11.5.2 Nippon Shinyaku Business Overview 89
11.5.3 Nippon Shinyaku Nucleic Acid Drugs Introduction 89
11.5.4 Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2020-2025) 90
11.5.5 Nippon Shinyaku Recent Development 90
11.6 Sobi 91
11.6.1 Sobi Company Details 91
11.6.2 Sobi Business Overview 91
11.6.3 Sobi Nucleic Acid Drugs Introduction 92
11.6.4 Sobi Revenue in Nucleic Acid Drugs Business (2020-2025) 93
11.6.5 Sobi Recent Development 93
11.7 Novartis 93
11.7.1 Novartis Company Details 93
11.7.2 Novartis Business Overview 94
11.7.3 Novartis Nucleic Acid Drugs Introduction 94
11.7.4 Novartis Revenue in Nucleic Acid Drugs Business (2020-2025) 95
11.7.5 Novartis Recent Development 95
11.8 BioNTech 96
11.8.1 BioNTech Company Details 96
11.8.2 BioNTech Business Overview 96
11.8.3 BioNTech Nucleic Acid Drugs Introduction 97
11.8.4 BioNTech Revenue in Nucleic Acid Drugs Business (2020-2025) 97
11.8.5 BioNTech Recent Development 98
11.9 Pfizer 98
11.9.1 Pfizer Company Details 98
11.9.2 Pfizer Business Overview 99
11.9.3 Pfizer Nucleic Acid Drugs Introduction 99
11.9.4 Pfizer Revenue in Nucleic Acid Drugs Business (2020-2025) 100
11.9.5 Pfizer Recent Development 100
11.10 Moderna Therapeutics 101
11.10.1 Moderna Therapeutics Company Details 101
11.10.2 Moderna Therapeutics Business Overview 102
11.10.3 Moderna Therapeutics Nucleic Acid Drugs Introduction 102
11.10.4 Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025) 103
11.10.5 Moderna Therapeutics Recent Development 103
11.11 Jazz Pharmaceuticals 104
11.11.1 Jazz Pharmaceuticals Company Details 104
11.11.2 Jazz Pharmaceuticals Business Overview 104
11.11.3 Jazz Pharmaceuticals Nucleic Acid Drugs Introduction 105
11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2020-2025) 106
11.11.5 Jazz Pharmaceuticals Recent Development 107
11.12 Novo Nordisk 107
11.12.1 Novo Nordisk Company Details 107
11.12.2 Novo Nordisk Business Overview 108
11.12.3 Novo Nordisk Nucleic Acid Drugs Introduction 108
11.12.4 Novo Nordisk Revenue in Nucleic Acid Drugs Business (2020-2025) 109
11.12.5 Novo Nordisk Recent Development 109
11.13 AstraZeneca 110
11.13.1 AstraZeneca Company Details 110
11.13.2 AstraZeneca Business Overview 111
11.13.3 AstraZeneca Nucleic Acid Drugs Introduction 111
11.13.4 AstraZeneca Revenue in Nucleic Acid Drugs Business (2020-2025) 112
11.13.5 AstraZeneca Recent Development 112
11.14 Astellas Pharma 113
11.14.1 Astellas Pharma Company Details 113
11.14.2 Astellas Pharma Business Overview 113
11.14.3 Astellas Pharma Nucleic Acid Drugs Introduction 114
11.14.4 Astellas Pharma Revenue in Nucleic Acid Drugs Business (2020-2025) 115
11.14.5 Astellas Pharma Recent Development 115
11.15 CureVac 115
11.15.1 CureVac Company Details 115
11.15.2 CureVac Business Overview 116
11.15.3 CureVac Nucleic Acid Drugs Introduction 116
11.15.4 CureVac Recent Development 117
11.16 Regulus Therapeutics 118
11.16.1 Regulus Therapeutics Company Details 118
11.16.2 Regulus Therapeutics Business Overview 118
11.16.3 Regulus Therapeutics Nucleic Acid Drugs Introduction 119
11.16.4 Regulus Therapeutics Recent Development 119
11.17 ProQR 120
11.17.1 ProQR Company Details 120
11.17.2 ProQR Business Overview 120
11.17.3 ProQR Nucleic Acid Drugs Introduction 121
11.17.4 ProQR Recent Development 121
11.18 Secarna 122
11.18.1 Secarna Company Details 122
11.18.2 Secarna Business Overview 122
11.18.3 Secarna Nucleic Acid Drugs Introduction 123
11.18.4 Secarna Recent Development 123
11.19 MiNA Therapeutics 124
11.19.1 MiNA Therapeutics Company Details 124
11.19.2 MiNA Therapeutics Business Overview 125
11.19.3 MiNA Therapeutics Nucleic Acid Drugs Introduction 125
11.19.4 MiNA Therapeutics Recent Development 126
11.20 Sylentis 126
11.20.1 Sylentis Company Details 126
11.20.2 Sylentis Business Overview 127
11.20.3 Sylentis Nucleic Acid Drugs Introduction 127
11.20.4 Sylentis Recent Development 128
11.21 Arrowhead 128
11.21.1 Arrowhead Company Details 128
11.21.2 Arrowhead Business Overview 129
11.21.3 Arrowhead Nucleic Acid Drugs Introduction 129
11.21.4 Arrowhead Recent Development 130
11.22 Silence Therapeutics 130
11.22.1 Silence Therapeutics Company Details 130
11.22.2 Silence Therapeutics Business Overview 130
11.22.3 Silence Therapeutics Nucleic Acid Drugs Introduction 131
11.22.4 Silence Therapeutics Recent Development 132
12 Analyst's Viewpoints/Conclusions 133
13 Appendix 135
13.1 Research Methodology 135
13.1.1 Methodology/Research Approach 135
13.1.2 Data Source 138
13.2 Author Details 141
13.3 Disclaimer 141